Beta

Enveric biosciences, inc.ENVB.US Overview

US StockHealthcare
(No presentation for ENVB)
OverviewAI AnalysisFinancialsFinancial ForecastStock SentimentalInstitutionsTradingView Chart

Ticker

Value

empty

There is no following symbol in this watchlist.

ENVB AI Insights

ENVB Overall Performance

ENVB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ENVB Recent Performance

4.31%

Enveric biosciences, inc.

-1.10%

Avg of Sector

-0.49%

S&P500

ENVB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

Check ENVB's Trend

ENVB Key Information

ENVB Valuation Metrics

ENVB Profile

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Price of ENVB

ENVB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ENVB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-14.69
PE Ratio (TTM)
-
Forward PE
23.09
PS Ratio (TTM)
0.08
PB Ratio
2.40
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-14.69
PE Ratio (TTM)
-
Forward PE
23.09
PS Ratio (TTM)
0.08
PB Ratio
2.40
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ENVB's latest earnings report released?

    The most recent financial report for Enveric biosciences, inc. (ENVB) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ENVB's short-term business performance and financial health. For the latest updates on ENVB's earnings releases, visit this page regularly.

  • How much cash does ENVB have?

    At the end of the period, Enveric biosciences, inc. (ENVB) held Total Cash and Cash Equivalents of 4.68M, accounting for 0.92 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ENVB's EPS continuing to grow?

    According to the past four quarterly reports, Enveric biosciences, inc. (ENVB)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.5. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ENVB?

    Enveric biosciences, inc. (ENVB)'s Free Cash Flow (FCF) for the period is -1.78M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 36.09% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of ENVB?

    The latest valuation data shows Enveric biosciences, inc. (ENVB) has a Price-To-Earnings (PE) ratio of -0.29 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.